Japan's Astellas Pharma is abandoning development of its Alzheimer's treatment FK962. Interim results of Phase II studies indicated that the drug would not be effective for the disease and the company decided not the pursue development. Astellas also announced that it has expanded it's agreed with Theravance to include Japan in their collaboration on the experimental antibiotic telavancin.
- see this press release on FK962
- read this report from MarketWire about the Astellas, Theravance deal
PLUS: Results from a mid-stage trial of Myriad Genetics' Flurizan demonstrated that the drug reduced the number of psychiatric episodes associated with Alzheimer's by 60 percent. Release